Subdermal Implant-bioabsorbable Oxandrolone Pellet For Rehabilitation Following Anterior Cruciate Ligament (ACL) Surgical Reconstruction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-31

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rehabilitation of knee stability and function after anterior cruciate ligament (ACL) reconstruction is slow and costly. The use of anabolic steroids, such as oxandrolone, may aid in the recovery of muscle mass and strength, as well as functional capacity. Oxandrolone, derived from dihydrotestosterone, has high anabolic activity and low androgenic activity (a 13:1 ratio), making it more effective in promoting weight gain with fewer side effects compared to other steroids. Registered by the FDA and previously by ANVISA (National Health Surveillance Agency (Brazil), it is indicated for cases of post-trauma or post-surgery weight loss. The subdermal use of oxandrolone implants is proposed to release the drug directly into the bloodstream, improving efficacy and reducing issues related to oral administration. This study evaluates the safety and tolerability of the absorbable subdermal oxandrolone implant for 24 weeks versus placebo implant in both men and women as an adjuvant treatment during rehabilitation following anterior cruciate ligament (ACL) surgical reconstruction. The serum and pharmacokinetic profile of the oxandrolone implant will be monitored.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

NCT00640146

Opioid-induced Constipation

COMPLETED PHASE2

Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

NCT01731730

Postsurgical Pain

COMPLETED PHASE2

Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

NCT02807428

Post-surgical Pain

COMPLETED PHASE2

Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

NCT02081703

Postsurgical Pain

COMPLETED PHASE2

Safety Study Investigating Local Tolerability and Pharmacokinetics of PXL01 in Healthy Volunteers

NCT00860080

Post-surgery Adhesion Formation

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase II, randomized, double-blind, placebo-controlled, multicenter clinical study designed to evaluate the safety and tolerability profile of the absorbable oxandrolone implant as an adjuvant treatment in rehabilitation following anterior cruciate ligament (ACL) reconstruction surgery. The primary safety outcome will be the incidence of serious adverse events (SAEs) collected through spontaneous reports and/or clinical findings over 24 weeks after randomization (subdermal insertion of the absorbable oxandrolone implant). The exploratory evaluation of the efficacy of the absorbable oxandrolone implant will compare the use of oxandrolone implant with a placebo pellet in the rehabilitation of patients after ACL reconstruction surgery will be based on its effects on muscle mass recovery, muscle strength, and functional capacity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anterior Cruciate Ligament (ACL) Reconstruction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oxandrolone

Absorbable oxandrolone implant (subdermal insertion) Men: 400 mg oxandrolone (two 200 mg oxandrolone implants each) Women: 200 mg oxandrolone (one 200 mg oxandrolone implant)

Group Type EXPERIMENTAL

Oxandrolone

Intervention Type DRUG

Absorbable oxandrolone implant (subdermal insertion) Men: 400 mg oxandrolone (two 200 mg oxandrolone implants each) Women: 200 mg oxandrolone (one 200 mg oxandrolone implant)

Placebo

Absorbable placebo implant (excipients; subdermal insertion) Men: 400 mg placebo (two 200 mg placebo implants each) Women: 200 mg placebo (one 200 mg placebo implant)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Absorbable placebo implant (excipients; subdermal insertion) Men: 400 mg placebo (two 200 mg placebo implants each) Women: 200 mg placebo (one 200 mg placebo implant)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxandrolone

Absorbable oxandrolone implant (subdermal insertion) Men: 400 mg oxandrolone (two 200 mg oxandrolone implants each) Women: 200 mg oxandrolone (one 200 mg oxandrolone implant)

Intervention Type DRUG

Placebo

Absorbable placebo implant (excipients; subdermal insertion) Men: 400 mg placebo (two 200 mg placebo implants each) Women: 200 mg placebo (one 200 mg placebo implant)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged between 18 and 45 years old
* Body weight between 50-110 kg for men and 40-90 kg for women
* BMI ≤30
* Complete rupture of the ACL as visualized by pre-operative magnetic resonance imaging
* Pre-operative radiographic examination with normal joint condition
* Having undergone knee arthroscopy surgery for anterior cruciate ligament reconstruction using autologous hamstring tendon graft
* No other associated injuries, such as posterior cruciate ligament (PCL) injury, grade III medial collateral ligament (MCL) injury, or severe concomitant injury in the contralateral knee (LCL)
* Very active, active, or irregularly active classification of type A or B by the International Physical Activity Questionnaire (IPAQ)
* Adherence to the rehabilitation protocol, having participated in at least 10 physical therapy sessions since the SV/V1.
* Functional range of motion from 0 to 120º and ability to walk without the aid of crutches.
* Sitting blood pressure in the clinic \<180/95 mmHg.
* Hematocrit ≤ 50%.
* ALT less than three times the upper limit of normal.
* Serum creatinine \<2 mg/dl.
* Bilirubin \< 3.0 mg/dl.
* Albumin \<3 g/dl or prealbumin \<10 mg/dl.
* PSA ≤ 4.1 ng/ml (men only).

Exclusion Criteria

* Only for female participants:
* Confirmed or suspected pregnancy
* History of childbirth, miscarriage, or lactation within the past 3 months
* Refusal to use permitted contraceptive methods during the study and for 90 days after study completion, unless surgically sterile or expressly declaring to be at no risk of pregnancy due to abstinence or non-reproductive sexual practices
* Clinical signs of hyperandrogenism
* Polycystic Ovary Syndrome (PCOS)
* Known or suspected breast carcinoma

Only for male participants:

-Known or suspected prostate or male breast carcinoma

For both male and female participants:

* Previous severe injury or history of surgery on the lower limbs
* Knee injury older than 12 months
* Unstable longitudinal meniscal tear
* Meniscus suture during ACL surgical reconstruction
* Use of patellar, quadriceps, or any graft other than hamstring tendon during ACL surgical reconstruction
* Known contraindication to hormone use
* Any condition that worsens with hormonal treatment
* Personal history of deep vein thrombosis (DVT)
* Known coagulopathy
* Known chromosomal disorders
* Hypersensitivity to anabolic androgenic steroids
* Previous failure of oxandrolone treatment
* Use of testosterone (or analogs) and other anabolic androgenic steroids in any pharmaceutical form within the last 3 months
* Pituitary tumor
* Creatinine levels \>2 mg/dl or history of chronic kidney disease
* Myocardial infarction within the last 6 months
* Uncontrolled dyslipidemia
* Uncontrolled diabetes
* Patients with chronic obstructive pulmonary disease (COPD) not responsive to bronchodilators
* Any contraindication to undergoing magnetic resonance imaging (MRI)
* Claustrophobia
* Sedentary classification according to the International Physical Activity Questionnaire (IPAQ)
* High-performance athlete
* Known psychiatric diagnosis, including major or persistent depressive disorder, bipolar disorder, anxiety disorders, social phobia, specific phobias, obsessive-compulsive disorder, psychotic disorders, personality disorders, eating disorders, neurocognitive disorders, developmental disorders, or somatoform disorders (somatization or hypochondriasis)
* Presence of urinary disorders
* Known diagnosis of fibromyalgia
* Current smoking
* History of drug abuse
* Participation in other clinical trial protocols within the past 30 days
* Participant who, in the investigator's opinion, presents other conditions or clinical/laboratory abnormalities that make them unsuitable to participate in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No